NCT01822756View on ClinicalTrials.gov

An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

August 31, 2016

Conditions
Solid TumorsPancreatic Cancer
Interventions
DRUG

ruxolitinib

DRUG

gemcitabine

Other names: Gemzar®

DRUG

nab-paclitaxel

Other names: Abraxane®

DRUG

filgrastim

Prophylactic GCSF support was filgrastim and was given in Cycle 1 on Days 2 to 5, 9 to 12, and 16 to 19, unless chemotherapy was held for toxicity, then prophylactic GCSF support was also held.

Trial Locations (5)

Unknown

Birmingham

Gainesville

Sarasota

Durham

Nashville

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT01822756 - An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter